368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

• Anh Nguyen,
• Adi Diab,
• Brendan Curti,
• Jonathan Zalevsky,
• Mary Tagliaferri,
• Christie Fanton,
• Evidio Domingo-Musibay,
• Wei Lin,
• Mehmet Bilen,
• Sandra D’Angelo,
• Andrew Brohl,
• Erkut Borazanci,
• Cat Haglund,
• Mona Vimal,
• Mann Muhsin,
• Mario Marcondes

Affiliations

Anh Nguyen

7Nektar Therapeutics, San Francisco, CA, USA

Adi Diab

2The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Brendan Curti

1 Providence Cancer Institute, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA

Jonathan Zalevsky

7Nektar Therapeutics, San Francisco, CA, USA

Mary Tagliaferri

7Nektar Therapeutics, San Francisco, CA, USA

Christie Fanton

7Nektar Therapeutics, San Francisco, CA, USA

Evidio Domingo-Musibay

5University of Minnesota Medical Center, Minneapolis, MN, USA

Wei Lin

7Nektar Therapeutics, San Francisco, CA, USA

Mehmet Bilen

3Winship Cancer Institute of Emory University, Atlanta, GA, USA

Sandra D’Angelo

8Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA

Andrew Brohl

4H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Erkut Borazanci

6HonorHealth Research Institute, Scottsdale, AZ, USA

Cat Haglund

7Nektar Therapeutics, San Francisco, CA, USA

Mona Vimal

7Nektar Therapeutics, San Francisco, CA, USA

Mann Muhsin

7Nektar Therapeutics, San Francisco, CA, USA

Mario Marcondes

7Nektar Therapeutics, San Francisco, CA, USA